Table 1.
The bead-based p-BNC is involved in six clinical trials through several major sponsors to target a number of diseases though the validation of a number of biomarkers.
| Study | Sponsor | Area | # Of Subjects | Clinical Site | Biomarkers |
|---|---|---|---|---|---|
| Development of A Lab-on-a-Chip System for Saliva-Based Diagnostics | National Institute of Dental and Craniofacial Research (NIDCR) | Cardiac Disease | 1,050 patients | Baylor College of Medicine | 15 proteins |
| Advanced Bio-Nano-Chips for Saliva-Based Drug Tests at the Point of Arrest | Home Office-Center of Applied Science and Technology (HO-CAST) | Drugs of Abuse | 340 participants | Baylor College of Medicine | 12 drugs |
| Texas Cancer Diagnostics Pipeline Consortium | Cancer Prevention Research Institute of Texas (CPRIT) | Ovarian Cancer | 2,660 patients | MD Anderson Cancer Clinic | 4 proteins |
| Cancer Prevention Research Institute of Texas (CPRIT) | Prostate Cancer | 1,100 patients | UT Health Science Center-San Antonio | 3 proteins | |
| Pilot and Prospective Studies for the Development of the Trauma Chip | Texas Emerging Technology Fund | Acute Kidney Failure | 120 patients | UT Health Science Center-Houston | 5 proteins |
| Development of p-BNCs for the Monitoring of Anti-Epilepsy Drugs Levels in Saliva | John S. Dunn Foundation | Epilepsy | 100 patients | UT Health Science Center-Houston | 3 proteins |